Immix Biopharma (IMMX) Institutional Ownership $2.17 -0.05 (-2.25%) (As of 12/20/2024 05:23 PM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Immix Biopharma (NASDAQ:IMMX)CurrentInstitutional OwnershipPercentage11.26%Number ofInstitutional Buyers(last 12 months)8TotalInstitutional Inflows(last 12 months)$1.16MNumber ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$627.43K Get IMMX Insider Trade Alerts Want to know when executives and insiders are buying or selling Immix Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data IMMX Institutional Buying and Selling by Quarter Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Immix Biopharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/16/2024 Geode Capital Management LLC150,082$224K0.0%+5.6%0.546% 10/22/2024 Private Advisor Group LLC34,325$51K0.0%-47.3%0.130% 8/16/2024 Invst LLC27,000$57K0.0%N/A0.102% 8/12/2024 XTX Topco Ltd17,663$35K0.0%-66.2%0.067% 8/9/2024 Renaissance Technologies LLC154,685$306K0.0%-41.7%0.586% 8/7/2024 AIGH Capital Management LLC1,406,680$2.79M0.9%-9.5%5.326% Get the Latest News and Ratings for IMMX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. 5/10/2024 Tocqueville Asset Management L.P.37,800$116K0.0%+89.0%0.143% 4/26/2024 Tritonpoint Wealth LLC24,526$75K0.0%N/A0.093% 2/7/2024 Jump Financial LLC18,500$128K0.0%N/A0.093% 2/6/2024 Private Advisor Group LLC99,775$690K0.0%N/A0.502% 2/1/2024OLD National Bancorp IN10,000$69K0.0%N/A0.050% 1/30/2024Imprint Wealth LLC34,483$239K0.2%+49.4%0.174% 11/9/2023 Tocqueville Asset Management L.P.12,000$41K0.0%N/A0.061% 10/23/2023Commonwealth Equity Services LLC28,855$99K0.0%+26.4%0.147% 7/28/2023 Koshinski Asset Management Inc.51,001$137K0.0%N/A0.339% 7/25/2023 UMB Bank n.a.72,639$195K0.0%-26.8%0.483% 4/11/2023 UMB Bank n.a.99,300$181K0.0%N/A0.714% 2/10/2023 Murchinson Ltd.67,200$154K0.0%N/A0.482% 2/7/2023Lynwood Capital Management Inc.25,000$58K0.1%N/A0.179% 2/1/2023 Bank of Montreal Can15,000$36K0.0%N/A0.108% 5/11/2022InterOcean Capital Group LLC15,900$38K0.0%N/A0.115% 2/14/2022 Altium Capital Management LP122,388$436K0.1%N/A1.616% 2/14/2022 Murchinson Ltd.695,600$2.48M0.2%N/A9.183% 2/9/2022 Context Capital Management LLC11,532$41K0.0%N/A0.152% 2/2/2022 PVG Asset Management Corp20,000$71K0.3%N/A0.264% 2/1/2022Eidelman Virant Capital29,856$103K0.0%N/A0.394% (Data available from 1/1/2016 forward) IMMX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of IMMX shares? During the previous two years, 17 institutional investors and hedge funds held shares of Immix Biopharma. The most heavily invested institutionals were AIGH Capital Management LLC ($2.79M), Renaissance Technologies LLC ($306K), Imprint Wealth LLC ($239K), Geode Capital Management LLC ($224K), UMB Bank n.a. ($195K), Murchinson Ltd. ($154K), and Koshinski Asset Management Inc. ($137K).Learn more on IMMX's institutional investors. What percentage of Immix Biopharma stock is owned by institutional investors? 11.26% of Immix Biopharma stock is owned by institutional investors. Learn more on IMMX's institutional investor holdings. Which institutional investors have been buying Immix Biopharma stock? Of the 14 institutional investors that purchased Immix Biopharma stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Private Advisor Group LLC ($99.78K), UMB Bank n.a. ($99.30K), Murchinson Ltd. ($67.20K), Koshinski Asset Management Inc. ($51.00K), Tocqueville Asset Management L.P. ($29.80K), Invst LLC ($27K), and Lynwood Capital Management Inc. ($25K). How much institutional buying is happening at Immix Biopharma? Institutional investors have bought a total of 492,486 shares in the last 24 months. This purchase volume represents approximately $1.79M in transactions. Which Immix Biopharma major shareholders have been selling company stock? The following institutional investors have sold Immix Biopharma stock in the last 24 months: AIGH Capital Management LLC ($148.32K), Renaissance Technologies LLC ($110.82K), XTX Topco Ltd ($34.53K), Private Advisor Group LLC ($30.85K), and UMB Bank n.a. ($26.66K). How much institutional selling is happening at Immix Biopharma? Institutional investors have sold a total of 351,180 shares in the last 24 months. This volume of shares sold represents approximately $699.15K in transactions. Related Companies SOPHiA GENETICS Institutional Ownership Biomea Fusion Institutional Ownership XBiotech Institutional Ownership Inhibrx Institutional Ownership Cardiff Oncology Institutional Ownership LifeVantage Institutional Ownership Silence Therapeutics Institutional Ownership Compass Therapeutics Institutional Ownership MacroGenics Institutional Ownership Candel Therapeutics Institutional Ownership This page (NASDAQ:IMMX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
